Quest Diagnostics Inc.
DGXQuest Diagnostics Inc. (DGX) is a leading provider of diagnostic testing, information, and services that help clinicians, health plans, and laboratories improve patient care. Founded in 1967 and headquartered in Irving, Texas, the company offers a broad range of laboratory testing services, including clinical chemistry, molecular diagnostics, and pathology, supporting healthcare providers with insights to inform treatment decisions.
Dividend History
Investors can expect a dividend payout of $0.80 per share, scheduled to be distributed in 5 days on January 28, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 28, 2026 | $0.80 | 2026-01-13 | 2026-01-13 |
| October 20, 2025 | $0.80 | 2025-10-03 | 2025-10-03 |
| July 21, 2025 | $0.80 | 2025-07-07 | 2025-07-07 |
| April 21, 2025 | $0.80 | 2025-04-07 | 2025-04-07 |
| January 29, 2025 | $0.75 | 2025-01-14 | 2025-01-14 |
Dividends Summary
- Consistent Payer: Quest Diagnostics Inc. has rewarded shareholders with 88 dividend payments over the past 22 years.
- Total Returned Value: Investors who held DGX shares during this period received a total of $32.37 per share in dividend income.
- Latest Payout: The most recent dividend of $0.80/share was paid 95 days ago, on October 20, 2025.
- Yield & Schedule: DGX currently pays dividends quarterly with an annual yield of 1.76%.
- Dividend Growth: Since 2004, the dividend payout has grown by 433.3%, from $0.15 to $0.80.
- Dividend Reliability: DGX has maintained or increased its dividend for 83 consecutive payments.
Company News
A consumer analysis examines how Taurus Medical, Inc. operates its telehealth TRT platform, which connects patients with licensed healthcare providers through OpenLoop Healthcare Partners. The analysis details the regulatory framework for testosterone as a Schedule III controlled substance, the three-entity operational structure (platform, provid...
The global Non-Invasive Prenatal Testing (NIPT) market is projected to grow at a CAGR of 17.01% from 2024 to 2031, reaching USD 9.83 billion from USD 2.8 billion in 2024. Growth is driven by rising demand for early fetal detection, advancements in next-generation sequencing technology, and increased adoption of safer prenatal testing methods. How...
The global autism spectrum disorder diagnostics market is projected to grow from $27.38 billion in 2024 to $43.36 billion by 2034, with a CAGR of 4.7%. Key growth drivers include increasing healthcare expenditure, R&D investments, and government initiatives. The autistic disorder segment will dominate at 52.82% market share, while early intervent...
Quest Diagnostics announced a quarterly cash dividend of $0.80 per share, payable on January 28, 2026 to shareholders of record on January 13, 2026.
Global fertility test market projected to grow from $7.92 billion in 2025 to $14.74 billion in 2033, driven by lifestyle changes, delayed pregnancies, and increasing infertility rates worldwide.
